"Innovators" relieved, Generics companies frustrated as government drops generic substitution plans for England
This article was originally published in Scrip
Executive Summary
The new UK coalition government has dropped plans to introduce automatic generic substitution in England because of uncertainty over whether the government's proposals would have provided real benefit to the National Health Service (NHS), says the Department of Health (DoH). Some parts of the pharmaceutical industry appeared to be relieved, but generics producers were frustrated.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.